INTRODUCTION
============

Maple syrup urine disease (MSUD) is an inherited metabolic disorder of branched-chain amino acids (BCAA): isoleucine, leucine and valine ([@b33-0050248]; [@b3-0050248]; [@b4-0050248]). It demonstrates an autosomal recessive pattern of inheritance, and affects ∼1 in every 185,000 children worldwide. However, much higher incidence rates are observed in Old Order Mennonite communities, with a ratio of 1:200 children, owing to founder effects. The first step of BCAA metabolism consists of a reversible transamination reaction to yield α-keto acids. The second step is oxidative decarboxylation of the α-keto acids by the mitochondrial branched-chain α-keto acid dehydrogenase (BCKD) complex. Mutation in any of the four genes encoding the three catalytic components of the BCKD complex has been shown to cause MSUD. Affected individuals accumulate BCAAs and α-keto acids in tissues and plasma, which cause the urine and bodily secretions to smell like maple syrup (burned sugar), hence the name of the disorder. In the most severe or 'classic' form of MSUD, the elevated BCAAs and α-keto acids can have a devastating impact on the central nervous system (CNS). If not treated, toxic build up of BCAAs and α-keto acids cause severe dystonia, coma, cerebral edema, dysmyelination and death within a couple weeks after birth. Treatment for MSUD typically consists of severe dietary restriction of BCAAs ([@b35-0050248]). However, even with a carefully monitored diet, secondary illnesses can lead to metabolic crisis and neurological damage, which is thought to generate the mental retardation and psychiatric problems that are often observed. An alternative treatment for MSUD is elective liver transplantation, which reduces plasma levels of BCAAs and α-keto acids and spares the CNS from severe injury ([@b34-0050248]). Unfortunately, the scarcity of livers for transplantation, surgical risks and lifetime usage of immunosuppressants limit this treatment option. A better understanding of the mechanisms that cause the neuropathology of MSUD and development of new therapeutic drugs could greatly benefit affected individuals as well as yield new insight into CNS metabolism.

To investigate the pathophysiology of MSUD, a mouse model of the classic form of the disease was created by deleting the gene encoding the E2 subunit of the BCKD complex ([@b17-0050248]). A model of a less severe form of the disease, intermediate MSUD, was also developed. These mice recapitulate several aspects of MSUD, including elevated levels of BCAAs and α-keto acids in tissues and plasma, severe neurological impairment, and decreased phenotypic severity in response to liver cell transplantation ([@b31-0050248]; [@b32-0050248]; [@b40-0050248]). However, the neuropathological mechanisms of MSUD remain poorly understood. Additional animal models could provide a complementary tool to study the mechanisms of this disease that generate CNS injury.

Developing zebrafish provide an excellent system to investigate the cellular and molecular mechanisms of MSUD. Although BCAA metabolism has yet to be described in this system, larval zebrafish offer several advantageous features, including small size, rapid development external to the mother, optical transparency, large clutch sizes and organ systems that are broadly similar to those in mammals. These features make zebrafish larvae readily amenable to a wide variety of behavioral, genetic, imaging, physiological and pharmacological approaches. The identification of zebrafish mutants with impaired BCKD complex function hold promise as a particularly useful tool to investigate the effects of disrupted BCAA metabolism.

Zebrafish perform a characteristic sequence of motor behaviors during development, which reflects different stages of locomotor network formation ([@b18-0050248]; [@b29-0050248]; [@b7-0050248]; [@b23-0050248]). These behaviors were used as the basis for extensive mutagenesis screens to identify mutants with specific defects in embryonic motility ([@b13-0050248]). Mutants that demonstrated similar, abnormal behavior were grouped into phenotypic classes, including the accordion class. Starting around 21 hours post-fertilization (hpf), wild-type embryos demonstrate smooth, alternating tail coils. By contrast, accordion class mutants compress along the rostro-caudal axis and relax, like an accordion. *Quetschkommode* (*que*) mutants were grouped into the accordion class but, outside of the initial study identifying these mutants, it has not been characterized nor has the identity of the mutated gene been reported.

In this study, we reveal that *que* mutants contain a mutation that disrupts the E2 subunit of the BCKD complex. Correspondingly, we present evidence that *que* mutants accumulate high concentrations of BCAAs. *que* larvae also contain reduced levels of the neurotransmitter glutamate, which probably contributes to the aberrant CNS function and abnormal behavior observed in this mutant. Combined, these data identify the *que* mutant as a vertebrate model of MSUD, which holds promise as a powerful tool to better understand this disease and identify therapeutic compounds.

RESULTS
=======

*que* mutants exhibit abnormal rostro-caudal compressions in response to touch
------------------------------------------------------------------------------

A single allele of *que* (*ti274*) was identified from a previously performed mutagenesis screen ([@b13-0050248]; [@b42-0050248]). The mutation is recessive, and homozygous mutants first demonstrate abnormal rostro-caudal compressions at around 72 hpf (data not shown). The abnormal behavior becomes more robust by 96 hpf. At this time point, high-speed video analysis shows that wild-type larvae respond to touch by first performing a large-amplitude body bend in which the nose touches the tip of the tail, a so-called C-start or C-bend (defined here as greater than 110°), followed by lower-amplitude body undulations to swim away ([Fig. 1A](#f1-0050248){ref-type="fig"}; supplementary material Movie 1) ([@b9-0050248]; [@b42-0050248]). By contrast, *que* mutants do not perform the initial C-bend or lower-amplitude body undulations, and instead demonstrate rostro-caudal shortening ([Fig. 1B](#f1-0050248){ref-type="fig"}; supplementary material Movie 2). This behavior, called accordion behavior ([@b13-0050248]), is due to abnormal coordination of axial left-right muscle contractions. Other mutants have been shown to demonstrate accordion behavior due to defects in either CNS function, such as *bandoneon* (*beo*), or muscle relaxation, such as *accordion* (*acc*) ([@b12-0050248]; [@b15-0050248]; [@b16-0050248]; [@b26-0050248]). We used kinematic analysis to compare the swimming behavior of wild-type, *beo*, *acc* and *que* larvae to each other to determine whether we could distinguish defects in CNS function from defects in muscle relaxation and classify *que* mutants. No clear trend emerged; however, *que* mutants consistently show the most dramatic disruption of swimming behavior compared with *acc* or *beo* mutants. Although *acc* and *beo* mutants demonstrate abnormal swimming behavior, C-bends are often observed ([Fig. 1C--E](#f1-0050248){ref-type="fig"}). By contrast, *que* mutants very rarely execute large-amplitude body bends ([Fig. 1F](#f1-0050248){ref-type="fig"}). *que* mutants continue to perform accordion behavior 5--6 days post-fertilization (dpf). They fail to inflate the swim bladder, which would enable them to feed, and eventually die around 7 dpf.

*que* mutants demonstrate abnormal motor output
-----------------------------------------------

To better examine whether *que* mutants harbor a defect in CNS function as opposed to a defect in muscle relaxation, we analyzed fictive locomotor output from the spinal cord by performing extracellular peripheral nerve recordings. Zebrafish larvae demonstrate bouts of motor output in response to touch ([Fig. 2A,B](#f2-0050248){ref-type="fig"}). These bouts are composed of tightly coordinated bursts that alternate rapidly between the left and right sides and orchestrate the axial muscle contractions that constitute swimming. In wild-type larvae, we observed rapid alternations in locomotor output between the left and right sides, with little overlap in bursting activity (6.5±6%, *n*=5; [Fig. 2C](#f2-0050248){ref-type="fig"}), as described previously ([@b22-0050248]). In *que* mutants, although the coordination of left-right locomotor activity was similar to wild-type siblings (compare [Fig. 2C with 2D](#f2-0050248){ref-type="fig"}), the amount of overlap between left-right bursting activity was significantly increased (19.1±11.3%, *n*=7, *t*=−2.3, *P*\<0.05). This increase in activity overlap is consistent with the abnormal coordination of left-right muscle contractions performed by *que* mutants. These data do not rule out the possibility that *que* mutants contain a defect in muscle relaxation; however, they do indicate that abnormal motor output from the CNS at least contributes to the behavior of this mutant.

To further characterize potential differences in locomotor output between wild-type and *que* mutant siblings, we examined a range of bout and burst properties related to rhythmic locomotor activity during fictive swimming ([@b22-0050248]). Although most of these properties were not significantly different between wild-type and mutant larvae ([Table 1](#t1-0050248){ref-type="table"}), *que* mutants generated a significantly greater number of bouts following touch stimulus applied to the head than did wild-type larvae \[11.6±6.2 bouts and 1.9±0.9 bouts, respectively (*t*=3.5, *P*\<0.01, *n*=5)\]. These results suggest that, compared with wild type, there are subtle, yet significant, changes in the locomotor circuit that underlie swimming in *que* mutant larvae and participate in generating the mutant behavioral phenotype.

The *que* gene encodes dihydrolipoamide branched-chain transacylase E2 (Dbt)
----------------------------------------------------------------------------

To determine the molecular identity of the *que* gene, we used a positional cloning strategy. Using a three-generation map cross panel, we screened pools of genomic DNA from wild-type siblings and homozygous mutants with a panel of simple sequence length polymorphism (SSLP) markers. *que* mapped to chromosome 22, which confirmed previous low-resolution mapping results ([@b11-0050248]). We then used DNA extracted from single embryos and single nucleotide polymorphism (SNP) markers to refine the map position to a 0.36 cM interval between the markers ENSDART109865 and wu:f63d09 ([Fig. 3A](#f3-0050248){ref-type="fig"}). Extensive genome database analysis and sequencing of nearby candidate genes led us to *dihydrolipoamide branched chain transacylase E2* (*dbt*), which encodes a subunit of the BCKD complex, which is required for BCAA metabolism. Zebrafish Dbt is a predicted 493 amino acids in length, and it is ∼78.2% identical to the human protein (data not shown). Mutations in the human *DBT* gene are known to cause MSUD, which can result in severe dystonia and death if not treated. Given that *que* mutants demonstrate abnormal behavior and nervous system function consistent with the severe dystonia observed in humans, we sequenced the *dbt* gene. Sequence analysis of the *dbt* gene from *que* homozygotes revealed a single nucleotide substitution in the splice donor site of exon 6 compared with wild type. The guanine of the intron side of this splice site is changed to an adenine ([Fig. 3B](#f3-0050248){ref-type="fig"}). To determine whether this change affects the splicing of intron 6, as would be predicted, we performed reverse transcriptase (RT)-PCR using one primer in exon 6 and one primer in exon 7 ([Fig. 3C](#f3-0050248){ref-type="fig"}). We found that RNA extracts from wild-type larvae were spliced according to prediction; however, RNA extracts from homozygous mutants revealed a larger transcript that contained the entire 86 base pairs of intron 6, indicating that it was spliced incorrectly (data not shown). This intron alters the sequence downstream of Lys268 and contains four stop codons, which would prematurely truncate the Dbt protein by 224 amino acids. *dbt* contains an acetyl transferase domain, essential for its function ([@b4-0050248]), which would be largely absent from the *que* mutant protein. Interestingly, in humans, a mutation that prematurely truncates the DBT protein at the orthologous position (Lys257) was reported in an individual with the most severe or 'classic' form of MSUD ([@b14-0050248]; [@b4-0050248]). These data indicate that the *que* mutation is a loss-of-function allele that diminishes or abolishes BCKD complex function.

![***que*** **mutants exhibit abnormal swimming behavior at 96 hpf.** (A,B) Selected frames from high-speed video recordings are shown with times indicated in milliseconds. (A) A wild-type larva demonstrates a normal C-bend (A4, asterisk) in response to a touch stimulus, followed by smaller-amplitude body undulations to clear the field (A5-A12). (B) A *que* mutant demonstrates abnormal rostro-caudal shortening and it fails to escape. (C--F) Kinematic traces are shown, with zero degrees indicating a straight body and positive and negative angles representing body bends in opposite directions. Time is shown in seconds. Ten representative traces are shown for each phenotype. (C) Wild-type embryos typically perform a C-bend (defined here as greater than 110°; asterisks) followed by smaller-amplitude body undulations. (D) *bandoneon* (*beo*) mutants, which contain a CNS defect and demonstrate behavior similar to *que*, sometimes perform a C-bend followed by abnormal body bends. (E) *accordion* (*acc*) mutants, which contain a muscle relaxation defect and also demonstrate behavior similar to *que*, sometimes perform a C-bend but fail to perform smaller-amplitude body bends. (F) *que* mutants rarely perform a C-bend and demonstrate few smaller-amplitude body undulations.](DMM008383F1){#f1-0050248}

###### 

Comparison of bout and burst properties related to fictive locomotor activity in wild type and *que* mutants

![](DMM008383T1)

![**The spinal locomotor output is altered in** ***que*** **mutants.** (A,B) Representative single extracellular peripheral nerve recordings from (A) wild type and (B) a *que* mutant. *que* mutants produce a greater number of bouts following a gentle tap to the head (arrow) than do wild type. (C,D) Representative paired (left-right) extracellular peripheral nerve recordings in which (C) wild type fish demonstrate tightly coordinated bursting activity with little overlap. By contrast, (D) *que* mutants generate greater bursting overlap. Gray bars denote burst activity in the top trace and extend to the bottom trace for ease of comparison.](DMM008383F2){#f2-0050248}

To further confirm the molecular identity of *que*, we injected wild-type embryos with either a standard control morpholino or a morpholino designed to block translation of *dbt*. Embryos were injected at the one- to four-cell stage and monitored over the course of development. Embryos injected with the standard control morpholino exhibited mostly normal behavior throughout the course of development (97.2% of surviving larvae, *n*=107; [Fig. 3D](#f3-0050248){ref-type="fig"}). Notably, 37.5% (*n*=144) of surviving larvae injected with the morpholino designed to target *dbt* demonstrated clear rostro-caudal compressions and fewer large-amplitude body bends at 96 hpf, similar to *que* mutants ([Fig. 3E](#f3-0050248){ref-type="fig"}). It is important to note that morpholinos are known to lose effectiveness at ∼4--5 dpf owing to turnover, which probably explains why not all embryos injected with the *dbt* morpholino demonstrated the robust accordion behavior performed by *que* mutants ([@b2-0050248]). We also attempted to perform rescue experiments in mutant embryos by injecting mRNA encoding *dbt* at the one- to four-cell stage and analyzing motility behavior at 4 dpf. We did not observe rescue (data not shown); however, mRNA is known to lose effectiveness ∼2 dpf owing to turnover. The *que* behavioral phenotype is not apparent until 3--4 dpf, which indicates that Dbt is required at this stage of development and precludes mRNA rescue. Regardless, the mapping data, nature of the *que* mutation, aberrant mRNA splicing observed in mutants, and morpholino phenocopy all argue that the *que* gene encodes Dbt.

*dbt* mRNA becomes enriched in the brain and gut organs during development
--------------------------------------------------------------------------

We next examined the spatial and temporal expression of *dbt* in developing zebrafish. RT-PCR revealed that *dbt* mRNA was present at all time points examined from 6 hpf to 120 hpf ([Fig. 4A](#f4-0050248){ref-type="fig"}). In situ hybridization also confirmed early expression. *dbt* was detected at the two-cell stage, indicating it is a maternally deposited mRNA ([Fig. 4B](#f4-0050248){ref-type="fig"}). The spatial expression of *dbt* is initially widespread through 24 hpf ([Fig. 4C,D](#f4-0050248){ref-type="fig"}); however, its expression pattern over the next few days of development becomes enriched in the brain and organs in the gut, such as liver and intestine ([Fig. 4E--H](#f4-0050248){ref-type="fig"}). These data suggest that *dbt* plays an important role in BCAA metabolism through function in these tissues. The prominent expression within the brain, in particular, suggests that *dbt* is important for CNS function. Intriguingly, the expression pattern of *dbt*, with progressive enrichment in the brain and gut organs over the course of development, is reminiscent of another mitochondrial protein that is important for CNS function, Opa3 ([@b28-0050248]).

*que* mutants harbor elevated levels of BCAAs
---------------------------------------------

In mammalian systems, impaired *DBT* function, as demonstrated by MSUD-affected individuals, results in elevated levels of BCAAs ([@b33-0050248]; [@b3-0050248]; [@b4-0050248]). Because *dbt* is disrupted in *que* mutants, we investigated their free amino acid profiles. Owing to the small size of larval zebrafish, a homogenate of 50 whole animals was used for each assay. We compared the free amino acid levels of wild-type and *que* mutant larvae at 96 hpf. Strikingly, *que* larvae harbor elevated levels of BCAAs ([Fig. 5A,B](#f5-0050248){ref-type="fig"}). Isoleucine, leucine and valine concentrations were 788%, 1006% and 688% (*n*=3, *P*\<0.01) of those of wild type, respectively. *que* mutants also showed a marked decrease in free glutamine levels, at 24% of wild-type (*n*=3, *P*\<0.01). In addition, statistically significant decreases were observed in the levels of a wide variety of free amino acids, including aspartate (16%), GABA (32%) and serine (28% of wild type; all *n*=3, *P*\<0.01); and alanine (44%), glutamate (38%), glycine (41%), methionine (49%) and threonine (60% of wild type; all *n*=3, *P*\<0.05). To rule out the possibility that abnormal motor behavior itself alters free amino acid levels, we examined *beo* mutants, which contain a mutation in the glycine receptor β2 subunit and exhibit abnormal behavior similar to *que* mutants ([Fig. 5C](#f5-0050248){ref-type="fig"}) ([@b16-0050248]). The free amino acid levels in *beo* mutants (*n*=1) were similar to that of wild-type controls, indicating that accordion behavior alone does not substantially alter free amino acid concentrations. Combined, these data provide strong evidence that mutation of the *que* gene results in an error in amino acid metabolism, yielding a prominent accumulation of BCAAs.

![**The*que*** **gene encodes dihydrolipoamide branched-chain transacylase E2 (Dbt), a subunit of the BCKD complex.** (A) *que* maps to a 0.36 cM interval on chromosome 22. Molecular markers are shown at the top and the number of recombinants out of the number of meiotic events are shown at bottom. *dbt* was positioned within the zero recombinant interval. (B) Chromatogram sequence traces of *dbt* from wild-type, hetero-and homozygous mutant larvae. The nucleotide substitution at the exon-intron boundary (G to A) can be observed in hetero- and homozygotes. (C) A schematic of the *dbt* protein is shown with the boundaries between exons indicated as vertical lines. Protein domains, including the acetyl transferase domain, are also shown. Below, the wild-type splice pattern is illustrated, with protein-coding exon 6, the sequence at the splice site, the intervening intron, and protein-coding exon 7 depicted. The *que* mutant splicing pattern is also illustrated, including the nucleotide substitution, which results in a failure to remove the intron. The intron contains four stop codons (asterisks). RT-PCR results using mRNA from wild type, *que* mutants and --RT controls are also shown using primers targeted towards exon 6 and exon 7. A larger DNA product, containing intron sequence, can be observed using mRNA isolated from *que* mutants. (D,E) Ten kinematic traces are shown for embryos injected with (D) the control morpholino or (E) a *dbt* translation-blocking morpholino. Embryos injected with the control morpholino perform C-bends (asterisk) and normal swimming behavior. *dbt* morphant embryos demonstrate abnormal swimming behavior and few large amplitude body bends, similar to *que* mutants.](DMM008383F3){#f3-0050248}

Glutamate levels are reduced in the brain of *que* mutant larvae
----------------------------------------------------------------

Although the neuropathology of MSUD is not well understood, reduced concentrations of neurotransmitters, including glutamate, were observed in the intermediate MSUD mouse model ([@b40-0050248]). Neurotransmitter depletion was found to correlate with abnormal motor behavior and a highly abnormal posture consisting of recumbency and stiff, extended limbs. Given that our analysis of the free amino acids levels in *que* mutants showed decreased concentrations of free glutamate and these mutants demonstrate abnormal CNS function and motor behavior, we examined the distribution of glutamate using an antibody. As a control for antibody penetration and overall tissue morphology, we also stained using an acetylated tubulin antibody. Antibody penetration and general morphology of the brain of *que* mutants seemed similar to wild type at 96 hpf (compare [Fig. 6A with 6D](#f6-0050248){ref-type="fig"}). By contrast, glutamate levels were markedly reduced in *que* mutant larvae (*n*=5 embryos, 12 sections, *P*\<0.01; compare [Fig. 6B with 6E](#f6-0050248){ref-type="fig"}, [Fig. 6G](#f6-0050248){ref-type="fig"}), which probably contributes to the abnormal nervous system function and behavior observed by this stage of development.

DISCUSSION
==========

In this study, we revealed that the *dbt* gene plays an essential role in developing zebrafish. The molecular nature of the *que* mutation, phenocopy through antisense morpholino injection, and the profile of free amino acid concentrations indicate that loss of *dbt* function result in abnormal amino acid metabolism and a dramatic accumulation of BCAAs. We determined that the *dbt* gene becomes enriched in the brain and organs in the gut during zebrafish development, and that impaired *dbt* function results in reduced levels of glutamate in the brain. Because glutamate is crucial for CNS function, the reduced levels of this neurotransmitter probably promote the abnormal spinal cord output and accordion behavior demonstrated by *que* mutants.

![***dbt*** **becomes enriched in the brain and organs in the gut across development.** (A) RT-PCR results are shown using mRNA isolated at different time points during zebrafish development. *dbt* was detected at all stages examined. --RT and β-actin controls are also shown. (B--H) In situ hybridization shows broad *dbt* expression at (B) the two-cell stage, (C) 12 hpf and (D) 24 hpf. The inset of a cross-section (the black bracket indicates the approximate level of the cross-section) reveals robust *dbt* expression in muscle. *dbt* expression become enriched in the brain and gut at (E) 48 hpf and (F) 96 hpf. (G) Sagittal sections of stained 96 hpf embryos illustrate expression in the brain (arrowhead) and gut. The white bracket indicates a portion of the region shown at higher magnification in H. Above the left edge of the white bracket, *dbt* expression in the liver can be observed, whereas above the right edge of the white bracket, *dbt* expression in the intestine is revealed.](DMM008383F4){#f4-0050248}

*dbt* is required for brain function in zebrafish
-------------------------------------------------

The findings from this study, as well as observations in rodent and human systems, suggest a model for how mutation of the zebrafish *dbt* gene leads to abnormal swimming. In mammalian systems, *dbt* is required for the second step of BCAA metabolism, and its impairment leads to elevated levels of BCAAs and α-keto acids in plasma and tissue ([@b3-0050248]; [@b4-0050248]). Elevated BCAAs in the plasma, in particular leucine, are thought to out-compete other amino acids at the blood-brain barrier, which results in neurotransmitter deficiencies, growth restrictions, cytotoxic edema, myelin disruption, and impaired energy metabolism throughout the CNS ([@b40-0050248]). α-keto acid toxicity has also been proposed to directly disrupt CNS function. Intracranial injection of α-ketovaleric acid, which is derived from valine, has been shown to elicit seizures in rats, whereas administration of other α-keto acids had no behavioral effect ([@b5-0050248]). In individuals with MSUD, reducing the concentrations of BCAAs and α-keto acids in the plasma by liver transplantation can protect CNS function and development ([@b34-0050248]).

We propose that very similar mechanisms regulate BCAA metabolism in zebrafish ([Fig. 7](#f7-0050248){ref-type="fig"}). Throughout the first 5 days of zebrafish development, the embryo consumes the presumptive equivalent of a high-protein diet in mammals by absorbing BCAA-containing proteins from the yolk ([@b21-0050248]; [@b36-0050248]). During the earliest stages of development, within the first few hours post-fertilization, the metabolic needs of the embryo are largely met by maternally derived mitochondria and mRNA ([@b24-0050248]; [@b39-0050248]; [@b1-0050248]). However, as embryogenesis proceeds, BCAA metabolism increasingly relies upon zygotic transcription. In wild-type embryos, BCKD complex function in the liver, other gut organs and the brain itself, protect the CNS from BCAA toxicity, similar to mammalian systems. According to this model, BCKD complex function supports appropriate import of amino acids into the CNS, robust metabolic generation of neurotransmitters, which are essential to support the coordinated CNS output that generates vigorous swimming behavior. In *que* mutants, our data indicate that mutation of *dbt* disrupts BCKD complex function to cause the toxic accumulation of BCAAs and, probably, α-keto acids. This error probably causes abnormal retention, metabolism and import of amino acids into the CNS, reduced levels of glutamate and other neurotransmitters, abnormal CNS function, and accordion behavior ([Fig. 7](#f7-0050248){ref-type="fig"}). It will be interesting to use transgenic approaches to determine whether restoring gene function in the liver of *que* mutants preserves normal CNS function, as shown in mammals ([@b34-0050248]; [@b31-0050248]; [@b32-0050248]). Driving gene expression in other organs not yet explored in mammals can also be investigated, which might indicate new therapeutic options for individuals with MSUD.

*que* mutants are a new animal model of MSUD
--------------------------------------------

*que* larvae harbor a mutation in zebrafish *dbt*, which results in elevated BCAA levels, similar to both the mouse models of MSUD and affected humans. In the mouse model of intermediate MSUD, elevated levels of BCAAs have been shown to correlate with progressive disruption of CNS function and concomitant defects in motor behavior that culminate in severe dystonia ([@b30-0050248]; [@b25-0050248]; [@b40-0050248]). Similarly, severe dystonia has been reported in MSUD-affected individuals during acute metabolic decompensation ([@b30-0050248]; [@b25-0050248]; [@b40-0050248]). *que* mutants demonstrate a progressive defect in motor behavior that culminates in abnormal CNS function and accordion behavior. Accordion behavior is probably the expression of severe dystonia in developing zebrafish. We and others have previously shown that zebrafish mutants that exhibit accordion behavior contain mutations in genes known to control movement and muscle tone in mammalian systems ([@b6-0050248]; [@b12-0050248]; [@b15-0050248]; [@b16-0050248]; [@b38-0050248]; [@b26-0050248]).

![**The free amino acid profile of** ***que*** **mutants shows elevated levels of BCAAs at 96 hpf.** The amino acids are referred to by their three-letter code, except for GABA. Each experiment contained a homogenate of 50 larvae. The error bars indicate standard error. (A) The free amino acid profile for wild-type larvae (*n*=3). (B) The free amino acid profile of *que* mutant larvae reveals a dramatic accumulation of BCAAs: isoleucine, leucine and valine. Other amino acid levels were reduced. *\** Significant difference from wild-type at *P*\<0.05; \*\* significant difference from wild-type at *P*\<0.01 (*n*=3). (C) The free amino acid profile of *beo,* a zebrafish mutant that demonstrates abnormal behavior owing to a CNS defect, indicates that abnormal behavior alone does not markedly alter free amino acid levels (*n*=1).](DMM008383F5){#f5-0050248}

![***que*** **mutants contain a reduced concentration of glutamate in the brain.** (A--F) Cross-sectional views of the hindbrain of 96 hpf larvae are shown. Immunohistochemistry using antibodies against acetylated tubulin, which predominantly labels axon tracts, reveals the overall structure of the brain and demonstrates tissue penetration of the antibodies. Staining using an antibody against L-glutamate illustrates the distribution of this neurotransmitter. (A) Labeling with the anti-acetylated tubulin reveals the axon tracts and overall structure of the hindbrain of wild-type larvae. (B) The hindbrain of wild-type larvae contains a broad distribution of L-glutamate. (C) The merged images show several L-glutamate-positive cells surrounded by anti-acetylated tubulin labeling. (D) The overall structure of the hindbrain of *que* mutants revealed by anti-acetylated tubulin appears similar to the hindbrain wild-type larvae. (E) The fluorescence intensity of labeling with the L-glutamate antibody is greatly reduced compared with wild type when imaged using the same microscope settings. However, increasing the gain of the confocal microscope shows more faint L-glutamate staining (inset). (F) The merged images show little L-glutamate staining compared with acetylated tubulin labeling. (G) The graph shows a significant reduction in L-glutamate staining intensity in *que* mutants normalized to acetylated tubulin staining. The fluorescent intensity values are the analog-to-digital converter values of the entire frame (*n*=5 embryos, 12 sections, \*\**P*\<0.01). Very similar results were obtained when a region of interest was selected to encompass a smaller, designated portion of the brain.](DMM008383F6){#f6-0050248}

The findings from this study indicate that *que* mutants are a new animal model of MSUD. One aspect of MSUD is the distinct, maple syrup smell of bodily secretions of affected individuals. We did not detect any distinct odor of *que* mutants (data not shown); however, this is probably due to the small size and minute amounts of secretions produced by larval zebrafish. Nevertheless, *que* larvae seem to recapitulate molecular, biochemical, cellular and behavioral aspects of MSUD. Because larval zebrafish contain a smaller nervous system than do mammalian systems, with fewer numbers of cells, *que* mutants provide a promising system to better characterize the progression of CNS injury in response to BCAA toxicity. Moreover, the small size, aquatic nature, development that is external to the mother and the ability to obtain large numbers of zebrafish embryos make them amenable to small-molecule screens ([@b41-0050248]). The behavioral phenotype of *que* mutants is robust and easily quantifiable; therefore, *que* mutants could be developed into a high-throughput system to screen libraries of compounds to identify small molecules that improve swimming behavior. Compounds that improve the behavioral phenotype of *que* mutants could be candidate therapeutics for individuals with MSUD.

![**A working model of how mutation of** ***dbt*** **results in abnormal, accordion behavior.** Similar to mammalian systems, we propose that wild-type zebrafish regulate metabolism of BCAAS via the BCKD complex. Many of these metabolic or molecular steps (black arrows) might occur in organs in the gut (such as the liver and intestine) but also the CNS. Amino acids (AA), such as glutamine, are transported across the blood-brain barrier and used to generate glutamate, GABA and other neurotransmitters (NT). These neurotransmitters are required for coordinated nervous system output to orchestrate swimming behavior. In *que* mutants, we propose that impaired BCKD function results in the accumulation of BCAA and α-keto acids. This yields reduced retention and metabolism, and reduced transport of other amino acids (white arrows) across the blood-brain barrier, yielding diminished neurotransmitter synthesis. The abnormal levels of neurotransmitters contribute to aberrant nervous system output and abnormal, accordion behavior. It is also possible that elevated concentrations of α-keto acids directly disrupt neural circuits to cause accordion behavior.](DMM008383F7){#f7-0050248}

Other aspects of MSUD can also be investigated using larval zebrafish. Gene targeting approaches can be readily employed, such as morpholino injection or zinc-finger nuclease technology, to model MSUD caused by disruption of other BCKD complex subunits ([@b10-0050248]; [@b2-0050248]). These technologies can also be used to examine the in vivo role of BCKD regulatory proteins, such as the BCKD phosphatase or kinase. Genetic modifier screens can also be performed using the *que* mutant to search for genes that can compensate for disruptions in BCAA metabolism. Taken together, these approaches can provide a promising platform to better understand CNS metabolism and develop new therapies to combat MSUD.

METHODS
=======

Zebrafish maintenance and breeding
----------------------------------

All animal protocols were approved by the Institutional Animal Care and Use Committees (IACUC) at the University of Massachusetts and the University of Minnesota. Zebrafish were raised and maintained according to standard procedures. Developing zebrafish were kept at 28.5°C in E3 media and staged according to morphological criteria ([@b19-0050248]; [@b27-0050248]). Experiments were performed using *que^ti^*^274^, *beo^ap21^* and *acc^tq206^* mutant alleles maintained on a mixed Tübingen (Tü) or tub longfin (TLF) genetic background.

Behavioral analysis
-------------------

To characterize swimming behavior, light-touch stimuli were applied to the head of larvae using a 1 mm insect pin. The response was recorded using a high-speed video camera (Fastec Imaging, San Diego, CA), recording 500--1000 frames per second, mounted to a 35 mm lens (Nikon, Melville, NY). The head-to-tail angle for each frame was measured using automated software developed by G.B.D.'s laboratory (Kelly Anne McKeown and Sandy Whittlesey unpublished). Briefly, pixel density analysis was used to identify three landmarks along the larval body: the tip of the nose, the border between the yolk ball and yolk extension, and the tip of the tail. These three points form an angle, and these angles were plotted over time using Microsoft Excel.

Electrophysiological recordings
-------------------------------

Zebrafish larvae at 4 dpf were anesthetized with 0.02% Tricaine-S (Western Chemical) in extracellular recording solution ([@b20-0050248]; [@b8-0050248]; [@b22-0050248]) and paralyzed with 0.1% (w/v) α-bungatoxoin (Sigma), which significantly reduced or abolished postsynaptic muscle activity based on patch recordings from muscle fibers ([@b22-0050248]). The extracellular solution was superfused continuously at 22--26°C. Larvae were pinned in a dorsoventral position to a Sylgard-lined glass-bottom Petri dish and the skin was removed. Extracellular suction electrode recording techniques were used to monitor the activity of peripheral nerves during fictive behavior ([@b22-0050248]). Activity occurred spontaneously but was also initiated by gently applying a touch stimulus to the head with a tungsten pin controlled and positioned by a manual micromanipulator (MX130, Siskiyou, Grants Pass, OR). The tip of the extracellular suction electrode (∼15 μm tip diameter) was positioned at the dorsoventral midline of a myotomal cleft where the skin had been removed. All extracellular recordings were restricted to between body segments 7 and 15. A MultiClamp 700B (Molecular Devices, Sunnyvale, CA) amplifier was used to monitor extracellular voltage in current-clamp mode at a gain of 1000 (*R~f~*=50 MO) with the low- and high-frequency cut-off at 100 and 4000 Hz, respectively. Recordings were sampled at 10 kHz. Extracellular recordings were digitized using a digitizing board (DigiData series 1440A, Molecular Devices, Sunnyvale, CA) acquired using pClamp 10 software and rectified offline.

Analysis of peripheral nerve activity
-------------------------------------

A program written in MATLAB (Mathworks, Natick, MA) was used to analyze the data. Estimates of mean burst frequency were determined from a Fourier transform, such that the initial estimate of mean burst frequency was the frequency at which the Fourier transform magnitude peaked over a frequency band from 0.1 to 5 Hz. The rectified voltage recordings were smoothed with a Gaussian-weighted moving average with 99% of the weight concentrated over an interval whose width was one-quarter of the reciprocal of the estimated burst frequency ('quarter-width').

The occurrence times of rhythmic bursts in the smoothed voltages were determined with an algorithm that searched for local peaks and troughs over quarter-width intervals while forcing adjacent peaks and troughs to be separated by at least quarter-width, and furthermore forcing peaks and troughs to alternate. With the peaks and troughs defined, the individual 'burst sections' were then defined as the interval between adjacent troughs. To determine the start of individual bursts, the burst-onset was defined as the time at which the smoothed waveform rose from the first trough to 10% of the way to the next peak. Similarly, burst-termination was defined as the time at which the smoothed waveform fell from the peak by 90% of the vertical distance to the next trough. Next, the analysis program was used to determine the bout and burst properties for each voltage trace in a manner similar to that used by Masino and Fetcho ([@b22-0050248]). Finally, the amount of overlap in activity between alternating (left-right) bursts was measured as the proportion of the total burst time occupied by the simultaneous activity in the paired (left-right) extracellular recordings ([Fig. 2C,D](#f2-0050248){ref-type="fig"}, overlap indicated by gray bars). The means and standard deviations for each parameter were then determined.

Chromosomal mapping and sequence analysis
-----------------------------------------

Crosses between fish heterozygous for the *que* allele and WIK fish were used to generate a three-generation map cross panel. F2 *que* mutant embryos and wild-type siblings were collected, sorted based upon the 96 hpf phenotype and stored in methanol at −20°C. DNA was extracted from more than 833 mutant larvae, and SSLP markers and SNP markers were obtained and generated against genes to refine the mapping interval. Exons and intron-exon boundaries of candidate genes were sequenced (Genewiz, South Plainfield, NY) from wild type, *que* siblings and homozygous mutants.

Morpholino analysis
-------------------

Wild-type zebrafish embryos were pressure injected at the one- to four-cell stage with 12 ng of morpholino designed to block translation of *dbt* or the standard control morpholino (Gene Tools, Phinomath, OR). This amount of morpholino was selected based upon dose-response experiments in which higher doses were found to generate morphological defects and/or lethality. The sequence of the translation-blocking morpholino was 5′-CGCACAG-TA[ATG]{.ul}ACCGCCGCCATCT-3′. Underlined residues indicate the start codon. The control morpholino sequence was 5′-CCTCTTAC-CTCAGTTACAATTTATA-3′. The embryos were raised at 28.5°C, and locomotive behavior was examined across development. Kinematic analysis, as described above, was performed at 96 hpf.

RT-PCR
------

RT-PCR was used to analyze mRNA splicing in mutants as well as examine expression during development. Primers designed against *dbt* protein-coding exon 6 (5′-ATCAAACTAAGCGAAG-TTGTCGG-3′) and exon 7 (5′-GCGCAACCGGACCAAC-3′) were used to amplify cDNA from wild-type and homozygous *que* mutant larvae. The primers used to amplify β-actin were 5′-CACACCGTGCCCATCTATGA-3′ and 5′ -AGGATCTTCATCAGGTAGTCTGTCAG-3′. The RNAs were reverse transcribed using the Omniscript kit (Qiagen, Venlo, The Netherlands). The *dbt* PCR products were sequenced for confirmation (Genewiz, South Plainfield, NY). RT-PCR reactions were performed multiple times to decrease the likelihood of amplification artifacts.

###### TRANSLATIONAL IMPACT

**Clinical issue**

Maple syrup urine disease (MSUD) is an inherited disorder that results in disrupted metabolism of branched-chain amino acids (isoleucine, leucine and valine), resulting in the toxic accumulation of these amino acids and their byproducts. This disease can have a devastating impact on the central nervous system (CNS), resulting in mental retardation, severe dystonia, coma or death if not treated. Although mouse models of the disease have been developed and some disease genes are known, the cellular and molecular mechanisms that promote brain injury in individuals with MSUD are not well understood.

**Results**

In this paper, the authors characterize a zebrafish mutant called *quetschkommode* (*que*) that exhibits defects in motor behavior. The mutation is found in the *dihydrolipoamide branched chain transacylase E2* (*dbt*) gene, a homolog of the human *DBT* gene, which can cause MSUD when mutated. In addition to abnormal behavior, *que* fish are shown to have disrupted metabolism of branched-chain amino acids and aberrant CNS function, mirroring features of human MSUD.

**Implications and future directions**

These data reveal the *que* zebrafish mutant to be a new animal model of MSUD. Because zebrafish offer a number of advantages for cellular, molecular, pharmacological and genetic analysis, the *que* mutant provides a unique tool to deepen our understanding of and develop new therapeutic options for this disease.

Whole-mount in situ hybridization
---------------------------------

Antisense digoxigenin probes were generated against *dbt* using cDNA (Genbank ID BC090917) acquired from Open Biosystems (Huntsville, AL). Whole-mount, colorimetric in situ hybridization was performed using established protocols ([@b37-0050248]) and examined using a compound microscope (Zeiss, Thornwood, NY) attached to a digital camera (Zeiss, Thornwood, NY). Cross-sections were generated by hand sectioning in situ hybridization stained embryos with a razor blade attached to a surgical blade holder. To generate sagittal sections, in situ hybridization stained embryos were embedded in 1.5% Agar and 5% sucrose. Blocks were kept in 30% sucrose solution overnight. The next day blocks were cut into 20 mm sections using a cryostat (Leica, Buffalo Grove, IL).

Amino acid quantification
-------------------------

For each amino acid quantification experiment 50 96-hpf larvae were sorted based upon the locomotor phenotype, were flash frozen in liquid nitrogen and stored at −80°C. The samples were homogenized and precipitated with 0.1 M lithium citrate, 3.3% 5-sulphosalicylic acid. The samples were sonicated for 10 minutes, then centrifuged at 4600 ***g*** for 20 minutes. The supernatant was then applied to VivaSpin500 size exclusion columns (Sartorium, Germany) and centrifuged at 15,000 ***g*** for 4 hours. The flow-through was stored at −80°C then sent to the University of California Davis California Genome and Proteomics Center to resolve free amino acid concentrations.

Antibody staining
-----------------

The tissue was prepared by embedding 96 hpf larvae as described for in situ hybridization. Double immunostaining was performed using standard protocols (similar to Downes and Granato) ([@b6-0050248]). The primary antibodies were rabbit anti-L-glutamate (1:100 dilution, ab9440; Abcam, Cambridge, MA) and mouse anti-acetylated tubulin (1:200 dilution, T6793; Sigma, St Louis, MO). Secondary antibodies were Alexa Fluor 488 goat anti rabbit (1:1000 dilution, A11034; Molecular Probes/Sigma, St Louis, MO) and Alexa Fluor 594 goat anti mouse (1:1000 dilution, A11005; Molecular Probes, Sigma, St Louis, MO). Images were acquired using a confocal microscope (Nikon, Melville, NY).

The fluorescent intensity for acetylated tubulin and L-glutamate antibody staining was quantified using the EZ Viewer program (Nikon, Melville, NY) by collecting entire frames (10,1283 μm^2^) or selecting a region of interest above the notochord (3060 μm^2^) for both channels. The numbers used for quantification are the analog-to-digital converter (ADC) values of L-glutamate normalized to acetylated tubulin.

Supplementary Material
======================

###### Supplementary Material
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